Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain
CompletedPhase 2NCT00108771
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The purpose of this study is to evaluate the effectiveness of the Matrix Fentanyl Patch ZR-02-01 in providing pain relief.
Study details
- Official title
- Double-Blind, Parallel, Randomized, Placebo-Controlled 12-Week Efficacy and Safety Assessment of ZR-02-01 in the Treatment of Chronic, Moderate to Severe Osteoarthritis (OA) Pain
- Conditions
- Interventions
- Drug: ZR-02-01 Fentanyl Transdermal Matrix Patch
- Drug: Placebo Patch
- Sponsor
- ZARS Pharma Inc.
- Start date
- 2004-04
- Primary completion
- 2006-09
- Sex
- All
- Age range
- from 40 Years to 75 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 13
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Adults between the ages of 40 and 75 years of age suffering from moderate to severe chronic pain caused by osteoarthritis. Exclusion Criteria: * Patient is already taking chronic opioids or has a history of substance abuse or has a substance abuse disorder.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT00108771